Welcome to 99nicu – Your Dedicated Community for Neonatal Care Professionals
At 99nicu, we offer more than just quick exchanges. We provide a space for lasting discussions for neonatal health care professionals. As a member, you’ll join a global network of NICU staff focused on exchanging clinical experiences and best practices.
Unlike fast-paced social media platforms, our community is designed for meaningful, sustained conversations. Find organized forums, webinars and valuable resources that you can revisit and search anytime. Our focus is long-term engagement, ensuring that each interaction contributes to your professional development and the advancement of neonatal care in your context.
Join today and experience a space where your expertise is valued and your contributions make a lasting impact.
Featured Content
-
Twenty Years of Unnecessary Pain
Twenty Years of Unnecessary Pain
If you are not familiar with the case, check Dotan’s cronology at the post: https://99nicu.org/forums/topic/3009-the-codeine-and-breastfeeding-controversy-2006-2026-how-a-flawed-case-report-reshaped-neonatal-guidelines-and-why-the-lancet-retracted-it-20-years-later/The Lancet has retracted the codeine case report that shaped two decades of postpartum analgesia. The retraction took twenty years. Mothers paid for every one of them.On 21 November 2026, The Lancet retracted a 2006 case report that blamed a newborn's death on morphine passed through breast milk. An institutional investigation found that key toxicology data had been left out of the paper, and concluded that the omission amounted to falsification.A retraction is supposed to close a chapter. This one should open a reckoning. For twenty years, a single case report told women who had just given birth that relieving their pain could kill their babies. Many believed it. Many of their doctors believed it too. And many women went home sore, sleepless and afraid, trying to breastfeed through pain that did not need to be there.One baby, one paper, one global rule The case is familiar to anyone who has worked in a postnatal ward since 2006. A baby boy died in Toronto in 2005, at under two weeks of age. His mother had been prescribed acetaminophen with codeine (Tylenol 3) after the birth. The authors proposed that she was an ultra-rapid CYP2D6 metabolizer, that she turned codeine into excess morphine, and that the morphine reached her son through her milk. The story was elegant, frightening and easy to teach. It was also built on an incomplete record. The SickKids Research Integrity Office found that the paper left out the infant's blood codeine and acetaminophen concentrations, and the finding of codeine in his stomach contents. Those are not footnotes. In 2020, Zipursky and Juurlink showed that the baby's blood codeine level was roughly 100 times higher than breastfeeding could explain. Codeine in an infant's stomach points to a different route of exposure altogether. The doubts were not new. The Lancet published a letter questioning the conclusions in 2008. Canadian Family Physician and the Canadian Pharmacists Journal retracted the related columns in 2020. The Lancet issued an expression of concern only in February 2026, after a New Yorker investigation and new allegations from a former member of the lead author's own lab. Meanwhile, the case travelled. It was cited hundreds of times and underpinned warnings from the FDA, the European Medicines Agency, Health Canada and ACOG. When the FDA recommended against codeine for breastfeeding women in 2017, the lead author of the retracted report was an author on seven of the 19 papers cited in support.How many women hurt for nothing? We will never have a precise number. No registry counts the perineal tears left undertreated, the cesarean wounds managed with "just paracetamol", or the mothers who chose to stop breastfeeding because they were told they had to choose. But codeine had been taken by millions of nursing mothers, and the warning reached all of them. It also spilled far beyond codeine. Fear of "opioids in the milk" became fear of analgesia in general. A lactating woman in pain became, first and foremost, a risk to be managed. This matters for the very thing the warnings claimed to protect. Pain is not a neutral bystander in lactation; it works against it.Pain inhibits the milk-ejection reflex. Stress and pain blunt oxytocin release, and classic physiology studies showed that distress can inhibit let-down. A mother bracing against pain at every feed is not well placed to release milk.Pain predicts early weaning. Breast and nipple pain are among the most common reasons women stop breastfeeding in the first weeks. Higher pain during labour has also been linked to breastfeeding cessation at 6–10 weeks.Pain predicts depression and chronic pain. In a prospective cohort of 1,288 women, the severity of acute pain after birth, not the mode of delivery, predicted persistent pain and depressive symptoms at 8 weeks. Each point of acute pain was associated with an 8.3% increase in depressive symptoms. The authors already noted, in 2008, that postpartum pain was undertreated partly because of breastfeeding fears. So the message "endure the pain to protect your baby" was not only unproven. It was counterproductive. It pushed women towards worse pain, worse mental health and shorter breastfeeding. Twenty years of pain, and twenty years of fear that the act of feeding their children might harm them.The patriarchy of evidence It is tempting to file this under individual misconduct and move on. We should not. One man's paper could only do this much damage because the system around it was ready to believe it. Lactating women have been excluded from drug research for generations, in the name of protecting them. The result is not protection; it is an evidence vacuum. Into that vacuum, a single dramatic case report from a prestigious institution became global policy. No trial was needed. No one asked how many mothers would be harmed by the alternative. Notice, too, where the burden of caution fell. Every warning was addressed to the mother. She had to monitor her baby for sedation. She had to choose between her own comfort and her child's safety. Her pain was treated as an acceptable cost; her baby's hypothetical risk was not. That asymmetry is not science. It is an old idea about women, that their suffering is natural, especially around childbirth, and that a good mother puts up with it. The same researcher founded Motherisk, a hospital laboratory whose hair-testing results were later found inadequate and unreliable. Those tests had been used in child-protection cases, against mothers. The pattern is hard to miss: authority concentrated in one expert, women's bodies treated as a source of danger, and mothers carrying the consequences. Women's health suffers when research is done about women rather than with them. It suffers when lactation is treated as a contraindication rather than as a physiological state that deserves its own pharmacology. And it suffers when the correction of an error takes twenty years, while the error itself took about a year to become a regulatory warning.Who profits from what we prescribe There is another actor in this story, and it is not a single author. Pain is a market, and analgesic prescribing has never been shaped by evidence alone. The North American opioid epidemic is the starkest example. Purdue Pharma launched OxyContin in 1996 with a nationwide campaign of sales visits, sponsored talks and payments to prescribers; within five years it was the most prescribed Schedule II narcotic in the United States. Later analyses found that the more opioid-related marketing payments doctors in a county received, the higher that county's prescription-opioid overdose deaths the following year. When Purdue pulled back under litigation, competitors stepped up their own promotion to the same prescribers. The codeine warnings did not land in a neutral space. Once codeine was off the table for nursing mothers, guidance pointed towards "strong" opioids instead, in a country where those were already being pushed hard. An unreliable case report and an aggressive industry pulled in the same direction: away from simple, cheap, well-known drugs. Brazil offers an instructive contrast. Here, dipyrone (metamizole) is one of the most used analgesics, sold over the counter and found in almost every home and maternity ward. In a national survey, non-opioid analgesics were used by 18.5% of respondents and opioids by only 0.5%. Dipyrone was never approved in the United States or Canada. My own view is that this cheap, off-patent, non-addictive drug probably helped spare Brazil an opioid tragedy on the American scale. We should not be complacent, though. Prescription opioid sales in Brazil rose between 2009 and 2015. And dipyrone's own lactation labelling is restrictive: the EMA advises against it during breastfeeding, while lactation services such as e-lactancia consider occasional single doses compatible. In other words, a drug that has served Brazilian women well is itself caught in the same thin evidence on lactation. The point is not that one molecule is good and another evil. It is that, when lactating women are left out of research, the gap is filled by whoever has the loudest voice: a charismatic expert, a regulator acting on a single case, or a company with a sales force.What we owe mothers now This retraction does not mean codeine is the ideal postpartum analgesic. Its effect varies with genotype, and better options exist. The lesson is not "codeine was fine after all". The lesson is that a lactating woman's pain is a clinical problem, and that it deserves the same rigour we give any other. For those of us in neonatal and perinatal care, that means a few concrete things:Treat maternal pain as part of lactation support. Ask about it at every feed assessment, not only about latch and weight.Use multimodal analgesia without apology. Paracetamol and NSAIDs are compatible with breastfeeding; short courses of appropriate opioids, with sensible monitoring, can be too.Retire the fear-based script. "Your medicine could hurt your baby" should never be the default sentence. Counsel with numbers, not dread.Check the foundations of what we teach. Ask, for any guideline we repeat, how many cases and trials actually sit underneath it.Demand that lactating women be included in research. Protection by exclusion has failed them. The Lancet has done the right thing, late. The rest is up to us. Twenty years of mothers were told that their pain was the price of their children's safety. It never was. The least we can do is make sure the next twenty years sound different.ReferencesThe Lancet. Retraction: Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 2026; 408 (21 Nov 2026).Koren G, Cairns J, Chitayat D, et al. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 2006; 368: 704. Retracted.Retraction Watch. Lancet retracts report by former SickKids pediatrician on infant's death from opioid poisoning. 20 Nov 2026.Retraction Watch. Lancet flags long-scrutinized report of infant poisoned by opioids in breast milk. 4 Feb 2026.Zipursky J, Juurlink DN. The implausibility of neonatal opioid toxicity from breastfeeding. Clin Pharmacol Ther 2020; 108: 964–970.Pimlott N, Tsuyuki RT. Risks of maternal codeine intake in breastfed infants: a joint statement of retraction. Can Fam Physician 2020.US FDA. Drug Safety Communication: restricting codeine and tramadol in children; recommending against use in breastfeeding women. 20 Apr 2017.Eisenach JC, Pan PH, Smiley R, et al. Severity of acute pain after childbirth, but not type of delivery, predicts persistent pain and postpartum depression. Pain 2008; 140: 87–94.Investigating the association between labor pain and cessation of breastfeeding. DOAJ.Breastfeeding-related pain among postpartum women: a mixed-methods study. J Psychosom Obstet Gynaecol 2019.Newton M, Newton NR. The let-down reflex in human lactation. J Pediatr 1948; 33: 698–704.Purdue Pharma's development and marketing of OxyContin (review of Purdue's OxyContin marketing). Indian J Med Ethics 2019.Hadland SE, et al. Association of pharmaceutical industry marketing of opioid products with mortality from opioid-related overdoses. JAMA Netw Open 2019 (coverage).University of Washington. Prescription opioid companies increased marketing after Purdue Pharma lawsuit. 9 Oct 2023.Analgesic use in Brazil: a population-based study (PNAUM). PLoS ONE 2019.Real world evidence of the use of metamizole (dipyrone) by the Brazilian population. Einstein (São Paulo) 2022.Krawczyk N, Greene MC, Zorzanelli R, Bastos FI. Rising trends of prescription opioid sales in contemporary Brazil, 2009–2015. Am J Public Health 2018; 108: 666–668.European Medicines Agency. EMA recommends aligning doses of metamizole medicines and their use during pregnancy and breastfeeding. 2018.e-lactancia. Metamizole. Updated Sept 2024.LactMed. Dipyrone. NCBI Bookshelf.-
-
- 1 reply
Featured by 99nicu.org -
-
The Codeine and Breastfeeding Controversy (2006-2026): How a Flawed Case Report Reshaped Neonatal Guidelines - and Why The Lancet Retracted It 20 Years Later
The Codeine and Breastfeeding Controversy (2006-2026): How a Flawed Case Report Reshaped Neonatal Guidelines - and Why The Lancet Retracted It 20 Years Later
Executive Summary and Clinical ContextFor nearly two decades, neonatal and obstetric clinical guidance regarding maternal analgesia was defined by an absolute prohibition: codeine is contraindicated during breastfeeding. Driven by warnings from the US Food and Drug Administration (FDA), European Medicines Agency (EMA), and health agencies worldwide, this dogma originated from a single 2006 case report in The Lancet describing the death of a 13-day-old infant from morphine overdose to which he was allegedly exposed via breast milk. The authors claimed that maternal ultrarapid cytochrome P450 2D6 (CYP2D6) metabolism converted standard postpartum codeine doses into a lethal concentration of morphine, which passed to the infant via breast milk.In response, clinical practice pivoted away from codeine toward higher-potency opioids such as oxycodone, hydromorphone, and fentanyl. Other mothers were advised to avoid breastfeeding while taking codeine or endured undertreated postpartum pain.Today, November 21, 2026, The Lancet formally retracted that landmark 2006 paper following an institutional investigation that confirmed scientific data falsification - specifically, the deliberate omission of toxicological and postmortem findings consistent with direct neonatal pill ingestion rather than transmission through breast milk. Below is an elaborate chronological history of this controversy, its pharmacological deconstruction, and the clinical implications for neonatal practice.Bottom line:This 20-year-long saga has reshaped postpartum pain management and lactational pharmacology, demonstrating a defensive and conservative approach, which may have been suboptimal by pushing mothers toward stronger opioids. Following its conclusion in a retraction of the seminal "Toronto case", we are reminded that clinical decision-making should not be based on isolated cases, no matter how tragic or outstanding. Such reports may trigger the "fallacy of misleading vividness", goading clinicians into unsubstantiated practices to avoid such remote and improbable outcomes. Moving forward, neonatal and perinatal care must remain anchored in rigorous pharmacokinetic modeling, robust epidemiological cohorts, and evidence-based multimodal analgesia.** Disclaimer: this post is based on the relevant publications (see reference list in the end) and was compiled and written with the assistance of Google NotebookLM. It was then thoroughly reviewed by myself before posting. Any additions or corrections are welcome. **Chronological Timeline of Events2005 ── Infant death (Toronto) 2006 ── Landmark Lancet case published; CPJ column 2007 ── CFP article; FDA Public Health Advisory 2008 ── Bateman et al. critique in Lancet; Motherisk case-control study 2009 ── Willmann PBPK modeling; Motherisk 4-day guidelines 2010 ── Fabricated "Baby Boy Blue" vignette published in Paediatr Child Health 2011 ── Confidential review uncovers concealed 300 ng/mL codeine and stomach pill residue 2012 ── Juurlink cohort (n=7,804 mother-infant pairs) shows no codeine harm 2013 ── Kelly et al. prospective tool (PLoS ONE); EMA/PRAC pediatric restrictions 2015 ── IJOA editorial challenges "numerator of one" 2020 ── Zipursky & Juurlink publish toxicological refutation; CPJ & CFP retract papers 2023 ── BMJ cohort (n=85,675 dyads) and Bateman/Hale editorial confirm relative infant safety 2026 ── New Yorker exposé; 123 CPS case disclaimers; Lancet Expression of Concern (Feb); Formal Retraction of Lancet paper (Nov 21) Detailed Chronological Development1. The Incident and the Original Report (April 2005 – August 2006)April 2005: In Toronto, Ontario, a healthy, full-term, 12-day-old infant exhibited poor feeding, lethargy, and grey skin, and was pronounced dead on day 13. His mother had taken Tylenol No. 3 (acetaminophen 300 mg, codeine 30 mg, caffeine 15 mg) for episiotomy pain, 2 tablets twice daily, and from the second day onward one tablet every 6 hours. Postmortem blood testing demonstrated a markedly elevated morphine concentration of 70 ng/mL.August 2006: Dr. Gideon Koren (Director of the Motherisk Program at Toronto's Hospital for Sick Children) and colleagues (including Ontario Deputy Chief Coroner Dr. James Cairns) published the case in The Lancet:Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder SJ. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 2006; 368(9536): 704.Genotyping revealed that the mother possessed a CYP2D6*2A allele with a CYP2D6*2x2 gene duplication (three functional copies), categorizing her as an ultrarapid metabolizer (UM). Koren posited that accelerated maternal metabolism resulted in excessive morphine excretion into breast milk (measured at 87 ng/mL in milk stored on day 10).The Omission: The paper omitted that the child's postmortem blood also contained 300 ng/mL of codeine and 5.9 µg/mL of acetaminophen, and that gastric contents contained visible white curdled material containing codeine.2. Regulatory Shockwaves and Practice Shifts (Late 2006 - 2007)Late 2006 - January 2007: Similar case accounts were published for Canadian practitioners:Madadi P, Koren G, Cairns J, et al. Maternal codeine is not safe for all breast-fed infants. Can Pharm J 2006; 139(6): 56–57.Madadi P, Koren G, Cairns J, et al. Safety of codeine during breastfeeding: fatal morphine poisoning in the breastfed neonate of a mother prescribed codeine. Can Fam Physician 2007; 53(1): 33–35.Unlike The Lancet, the Canadian columns disclosed the neonatal acetaminophen level (5.9 µg/mL), but did not highlight its toxicological incompatibility with breast milk transfer.Late 2007: Direct regulatory reaction ensued:US FDA. Public Health Advisory: Use of Codeine By Some Breastfeeding Mothers May Lead To Life-Threatening Side Effects In Nursing Babies. (December 2007).Health Canada and European authorities mirrored this advisory, leading to widespread class warnings.Clinical Practice Consequence: Obstetric units shifted away from codeine to more potent opioids such as oxycodone, hydromorphone, and fentanyl.3. Toxicological Debate and Pharmacokinetic Modeling (2008 – 2010)August 2008: Toxicologists D. Nicholas Bateman, Michael Eddleston, and Euan Sandilands challenged the biological plausibility of the report in The Lancet:Bateman DN, Eddleston M, Sandilands E. Codeine and breastfeeding. Lancet 2008; 372(9639): 625.Madadi P, Chitayat D, Koren G. Codeine and breastfeeding – Authors' reply. Lancet 2008; 372(9639): 626.Ferner RE. Did the drug cause death? Codeine and breastfeeding. Lancet 2008; 372(9639): 606–608.Bateman and colleagues calculated that even under maximal conversion, an infant consuming normal volumes of milk could not ingest a lethal morphine dose. Koren and Madadi responded by attributing the discrepant postmortem drug levels to postmortem redistribution.December 2008: Motherisk published a case-control study linking maternal codeine use to reported infant sedation:Madadi P, Ross CJ, Hayden MR, et al. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. Clin Pharmacol Ther 2009; 85(1): 31–35.2009: Motherisk formulated clinical guidelines:Madadi P, Moretti M, Djokanovic N, et al. Guidelines for maternal codeine use during breastfeeding. Can Fam Physician 2009; 55(11): 1077–1078.These guidelines state that:In most cases, the occurrence of CNS depression is consistent between the mother and the baby. If the mother suffers from symptoms of CNS depression (eg, somnolence, grogginess), a physician should examine the baby for signs of CNS depression as well.If the baby is not fed well, does not wake up to be fed, does not gain weight, or shows limpness, he or she should be examined by a physician.Central nervous system depression in the baby appears to worsen after 4 days, probably owing to the accumulation of morphine with more breastfeeding. If possible, codeine should not be used for longer than 4 days. If pain still necessitates codeine, an attempt should be made to decrease the dose or to switch to non-codeine painkillers (eg, NSAIDs).Women who convert more codeine to morphine have a duplication of the gene encoding for cytochrome P450 2D6. This genetic predisposition can be detected by genetic test. This test, although not available in most hospitals, is available on the market.Although codeine is widely used in North America, 9 randomized studies comparing the use of codeine with various NSAIDs in laparotomy cases (ie, abdominal surgery) failed to show codeine to be superior in pain relief.December 2009: Stefan Willmann and colleagues performed physiologically based pharmacokinetic (PBPK) modeling:Willmann S, Edginton AN, Coboeken K, Ahr G, Lippert J. Risk to the breast-fed neonate from codeine treatment to the mother: a quantitative mechanistic modeling study. Clin Pharmacol Ther 2009; 86(6): 634–643.The simulation showed that fatal neonatal morphine accumulation from breast milk was physiologically implausible unless the neonate suffered from near-total or complete cessation of renal clearance.November 2010: A case vignette featuring "Baby Boy Blue" - a neonate with lethargy, miosis, and bradypnea reportedly saved with naloxone after breast milk exposure from an ultrarapid metabolizer mother - was published:Rieder M, Koren G. Baby boy blue – why is this newborn lethargic? Paediatr Child Health 2010; 15(9): 571–572. (This case was later admitted to have been entirely fabricated, alongside 123 others):Society Note on 123 papers to add disclaimer:This is a correction to: Paediatrics & Child Health, Volume 15, Issue 9, November 2010, Pages 571–572, https://doi.org/10.1093/pch/15.9.571Disclaimer: Every clinical vignette presented within the journal's CPSP Highlights section describes a fictional case, created as a teaching tool and related to a Canadian Paediatric Surveillance Program (CPSP) study or survey.4. The Confidential Investigation and Epidemiological Studies (2010 - 2015)2010–2011: Alerted by Nick Bateman, Toronto toxicologist Dr. David Juurlink reviewed the Ontario Coroner's confidential case file. He discovered the undisclosed neonatal postmortem blood codeine level of 300 ng/mL and pathologist notes documenting white tablet residue in the infant's stomach. In November 2011, Juurlink submitted an official memorandum to the Ontario Chief Coroner, but the office declined to re-open the case.May 2012: Juurlink and colleagues published a population-based cohort study of 7,804 mother-infant dyads:Juurlink DN, Gomes T, Guttmann A, et al. Postpartum maternal codeine therapy and the risk of adverse neonatal outcomes: a retrospective cohort study. Clin Toxicol (Phila) 2012; 50(5): 390–395.Infants of mothers prescribed codeine showed no increased risk of hospital readmission (HR 0.95; 95% CI 0.81–1.11), resuscitation/ventilation, or death.July 2013: Kelly, Koren, and colleagues evaluated the 2009 guidelines in a prospective cohort of 238 mothers:Kelly LE, Chaudhry SA, Rieder MJ, et al. A Clinical Tool for Reducing Central Nervous System Depression among Neonates Exposed to Codeine through Breast Milk. PLoS ONE 2013; 8(7): e70073.Neonatal sedation was reported in 2.1% of infants, only when codeine use exceeded 4 days, with no cases in CYP2D6 UM mothers.2013: European regulatory bodies enacted broader restrictions:European Medicines Agency (EMA) / CMDh. Restrictions on use of codeine for pain relief in children – CMDh endorses PRAC recommendation. (June 2013).2015: Anaesthetists challenged the regulatory consensus:Halder S, Russell R, Quinlan J. Codeine and breast-feeding mothers. Int J Obstet Anesth 2015; 24(1): 5–7.The authors criticized national guidance (such as NICE) for basing restrictive policies on an unverified "numerator of one".5. Toxicological Refutation and Initial Retractions (2020 – 2023)May 2020: Jonathan Zipursky and David Juurlink formally published the concealed forensic evidence and toxicological analysis:Zipursky J, Juurlink DN. The Implausibility of Neonatal Opioid Toxicity from Breastfeeding. Clin Pharmacol Ther 2020; 108(5): 964–970.They demonstrated that:The infant's postmortem blood codeine level was 300 ng/mL (~50 times higher than expected from breast milk transfer).With a morphine milk concentration of 87 ng/mL, had the infant ingested 1,000 mL of milk/day (which is considerably higher than expected for an infant of similar weight), the total amount of morphine ingested via milk would have been roughly 87 µg/day, far below the standard pediatric oral therapeutic dose of ~3,200 µg/day for a 4 kg neonate.Normal hydration (the pediatrician documented weight recovery and 5 wet diapers the day before death) ruled out the severe anuria required for accumulation.November 2020: Following an invited expert peer review, Canadian journals (CPJ and CFP) issued a formal joint retraction:Tsuyuki RT, Pimlott N. Risks of maternal codeine intake in breast-fed infants: A Joint Statement of Retraction from the Canadian Pharmacists Journal and Canadian Family Physician. Can Pharm J (Ott) 2020; 154(1): 7–8 / Can Fam Physician 2020; 66(11): 793–796.March 2023: In The BMJ, Zipursky, Juurlink, and colleagues published a cohort study of 85,675 propensity-score-matched mother-infant dyads:Zipursky JS, Gomes T, Everett K, et al. Maternal opioid treatment after delivery and risk of adverse infant outcomes: population based cohort study. BMJ 2023; 380: e074005.Maternal opioid prescriptions showed no association with infant hospital readmission (HR 0.98; 95% CI 0.93-1.03), NICU admission (HR 1.12; 95% CI 0.94-1.32), or assisted ventilation (HR 0.87; 95% CI 0.60-1.26), with zero deaths. Infants of mothers prescribed codeine were significantly less likely to require readmission (HR 0.74; 95% CI 0.66-0.83), which may reflect residual confounding and should not necessarily be viewed as a protective effect.An editorial accompanying the abovementioned stated that: "The relative infant dose (bioavailability (in mg/kg) in the infant expressed as a percentage of bioavailability in the mother) is rarely >10%, indicating that both clinical effects and toxicity are unlikely. The relative infant dose for codeine, for example, is 0.6-8.1%. Subsequent effects in infants depend on metabolism that may activate or eliminate the drug. Although enzymes that metabolise drugs may not be fully developed in premature infants, toxicity is generally unlikely as relative infant doses are so low."Bateman DN, Hale TW. Opioid analgesia for breastfeeding mothers: New study reports reassuring evidence on safety for infants. BMJ 2023; 380: p514.6. The New Yorker Exposé and Retraction of The Lancet Paper (2026)January 2026: Ben Taub published an investigative exposé:Taub B. Did a Celebrated Researcher Obscure a Baby's Poisoning? The New Yorker (January 26, 2026).The article revealed that Parvaz Madadi was listed on drafts she had never seen, that Koren privately claimed the infant's stomach contained morphine to negate direct pill administration, and that Michael Rieder acknowledged the 2010 "Baby Boy Blue" case was fabricated.January – March 2026:Parvaz Madadi wrote to The Lancet on January 20, 2026, requesting retraction due to data falsification (as reported in the BMJ News: Dyer O. Breastfeeding and codeine guidance in doubt after calls for retraction of pivotal Lancet study BMJ 2026; 392 :s498 doi:10.1136/bmj.s498).Paediatrics & Child Health issued blanket disclaimers on 123 papers (including "Baby Boy Blue"), clarifying they were fictional vignettes.The Lancet editors publish an official expression of concern: Expression of Concern: Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 2026; 407(10528): 659.May 2026:Dr. Michael Rieder published a briefing paper debating neonatal pharmacokinetics and acknowledging the rarity of potential lethal exposure to morphine via breast milk, while maintaining that such cases can occur and that clinicians need to be aware of this.He also states that: "Short courses of codeine therapy (less than 3 days) are likely to be safe, while consideration should be made for the use of alternate therapy should longer term therapy be necessary."Rieder M. Codeine toxicity via breast Milk: Can this occur and implications for opiate therapy in children. Br J Clin Pharmacol 2026; 92(9): 3012–3016.November 21, 2026: The Research Integrity Office of The Hospital for Sick Children, Toronto, Canada concluded that omitting the infant's blood codeine, blood acetaminophen, and gastric codeine findings from the original case report constituted scientific falsification, prompting formal retraction by the Lancet:The Editors of The Lancet. Retraction: Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 2026; 408: 1812.Springer Publishing / DailyNurse. Codeine and Breastfeeding: What Clinicians Need to Know After the Lancet Retraction. (November 2026).Forensic and Pharmacokinetic ComparisonThe following table contrasts the incomplete data published in The Lancet (2006) with the full forensic profile established by postmortem toxicology and re-investigation:Analytical ParameterAs Reported in The Lancet (2006)Complete Postmortem Findings (Zipursky & Juurlink, 2020)Neonatal Pharmacological SignificancePostmortem Blood Morphine70 ng/mL70 ng/mLNormal therapeutic analgesic plasma concentrations in neonates receiving IV morphine are 10-15 ng/mL; 70 ng/mL is potentially lethal.Postmortem Blood CodeineNot reported (omitted)300 ng/mL~50 times higher than peak neonatal levels from breast milk (~2.2 ng/mL); indicates massive direct ingestion of codeine.Postmortem Blood AcetaminophenNot reported (omitted)5.9 µg/mLIncompatible with milk transfer; acetaminophen has minimal postmortem redistribution.Gastric ContentsNot reported (omitted)Curdled white material containing codeineDirect physical evidence of crushed tablet administration into the stomach.Maternal Breast Milk Morphine87 ng/mL (stored day 10)87 ng/mLAt 87 ng/mL, consuming 1,000 mL/day provides only 87 µg/day of morphine.Relative Infant Dose (RID) - MorphineNot calculated<1.2%Standard pediatric safety cutoff is <10%. Normal neonatal oral therapeutic dosing is up to 3,200 µg/day.Renal Function StatusPresumed "immature"Normal hydration and urine outputPediatrician documented birth weight recovery and 5 wet diapers the day before death, refuting the anuric accumulation required by PBPK models.Key Takeaways for Neonatal and NICU PracticeLactational Opioid Transfer is Naturally Constrained: All opioids transfer into mature breast milk in small quantities. Standard therapeutic maternal doses yield an RID well below the 10% threshold. Fatal neonatal accumulation is highly unlikely via breast milk in a thriving infant with preserved renal clearance. For premature or otherwise ill neonates, an individualized decision-making process and monitoring scheme should be undertaken.Beware the Substitution of Riskier Alternatives: Replacing codeine with high-potency opioids (oxycodone, hydromorphone, fentanyl) increases maternal dependence liability, diversion hazards, and potential neonatal adverse effects.Current Standard of Care (Stepwise Multimodal Analgesia): Postpartum pain should be managed with scheduled non-opioids (ibuprofen and acetaminophen) as the foundational tier. If breakthrough opioids are required, short courses (≤3-4 days) should be used. Mothers should be educated to monitor for extreme somnolence in themselves and poor latch, feeding difficulties, or limpness in their infants.ReferencesBateman DN, Eddleston M, Sandilands E. Codeine and breastfeeding. Lancet 2008; 372(9639): 625.Bateman DN, Hale TW. Opioid analgesia for breastfeeding mothers: New study reports reassuring evidence on safety for infants. BMJ 2023; 380: p514.Canadian Paediatric Society. Society note on 123 papers to add disclaimer. Paediatr Child Health 2026.Dyer O. Breastfeeding and codeine guidance in doubt after calls for retraction of pivotal Lancet study. BMJ 2026; 392: s498.European Medicines Agency (EMA) / CMDh. Restrictions on use of codeine for pain relief in children – CMDh endorses PRAC recommendation. 2013.Ferner RE. Did the drug cause death? Codeine and breastfeeding. Lancet 2008; 372(9639): 606–608.Halder S, Russell R, Quinlan J. Codeine and breast-feeding mothers. Int J Obstet Anesth 2015; 24(1): 5–7.Juurlink DN, Gomes T, Guttmann A, et al. Postpartum maternal codeine therapy and the risk of adverse neonatal outcomes: a retrospective cohort study. Clin Toxicol (Phila) 2012; 50(5): 390–395.Kelly LE, Chaudhry SA, Rieder MJ, et al. A Clinical Tool for Reducing Central Nervous System Depression among Neonates Exposed to Codeine through Breast Milk. PLoS ONE 2013; 8(7): e70073.Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder SJ. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 2006; 368(9536): 704. [RETRACTED]Madadi P, Koren G, Cairns J, et al. Maternal codeine is not safe for all breast-fed infants. Can Pharm J 2006; 139(6): 56–57. [RETRACTED]Madadi P, Koren G, Cairns J, et al. Safety of codeine during breastfeeding: fatal morphine poisoning in the breastfed neonate of a mother prescribed codeine. Can Fam Physician 2007; 53(1): 33–35. [RETRACTED]Madadi P, Chitayat D, Koren G. Codeine and breastfeeding – Authors' reply. Lancet 2008; 372(9639): 626.Madadi P, Ross CJ, Hayden MR, et al. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. Clin Pharmacol Ther 2009; 85(1): 31–35.Madadi P, Moretti M, Djokanovic N, et al. Guidelines for maternal codeine use during breastfeeding. Can Fam Physician 2009; 55(11): 1077–1078.Rieder M, Koren G. Baby boy blue – why is this newborn lethargic? Paediatr Child Health 2010; 15(9): 571–572.Rieder M. Codeine toxicity via breast Milk: Can this occur and implications for opiate therapy in children. Br J Clin Pharmacol 2026; 92(9): 3012–3016.Springer Publishing / DailyNurse. Codeine and Breastfeeding: What Clinicians Need to Know After the Lancet Retraction. 2026.Taub B. Did a Celebrated Researcher Obscure a Baby's Poisoning? The New Yorker (January 26, 2026).The Editors of The Lancet. Expression of Concern: Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 2026; 407(10528): 659.The Editors of The Lancet. Retraction: Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 2026; 408: 1812.Tsuyuki RT, Pimlott N. Risks of maternal codeine intake in breast-fed infants: A Joint Statement of Retraction from the Canadian Pharmacists Journal and Canadian Family Physician. Can Pharm J (Ott) 2020; 154(1): 7–8 / Can Fam Physician 2020; 66(11): 793–796.US Food and Drug Administration (FDA). Public Health Advisory: Use of Codeine By Some Breastfeeding Mothers May Lead To Life-Threatening Side Effects In Nursing Babies. 2007.Willmann S, Edginton AN, Coboeken K, Ahr G, Lippert J. Risk to the breast-fed neonate from codeine treatment to the mother: a quantitative mechanistic modeling study. Clin Pharmacol Ther 2009; 86(6): 634–643.Zipursky J, Juurlink DN. The Implausibility of Neonatal Opioid Toxicity from Breastfeeding. Clin Pharmacol Ther 2020; 108(5): 964–970.Zipursky JS, Gomes T, Everett K, et al. Maternal opioid treatment after delivery and risk of adverse infant outcomes: population based cohort study. BMJ 2023; 380: e074005.-
-
- 1 reply
Featured by 99nicu.org -
-
European survey on procedural sedation and analgesia in neonates
European survey on procedural sedation and analgesia in neonates
Dear colleague,Together with a group of neonatologists, I developed a survey on procedural sedation and analgesia in neonates. Procedures like intubations, LISA/MIST, catheter placements and chest drain insertions are amongst the painful procedures performed in NICUs. Currently, there are no clear international guidelines for sedation and analgesia for neonates undergoing these procedures. The aim of this study to get insights in current practices of procedural sedation and analgesia across Europe.We would like to reach neonatologists (in training) working in European hospitals and kindly ask them to complete this survey. Responses from multiple neonatologists within the same NICU are encouraged, as clinical practices may vary between individual neonatologists.The survey takes approximately 10-15 minutes to complete and can be accessed through the following link: https://esurvey.erasmusmc.nl/servicebedrijf/ls/index.php?r=survey/index&sid=797838&lang=enWe would greatly appreciate your valuable participation. If you have any questions or comments, please contact v.blok@erasmusmc.nlYours sincerely,Veerle Blok, Medical student, Erasmus University Rotterdam - Erasmus MC, The Netherlands.Judith ten Barge, PhD, Erasmus MC – Sophia Children’s Hospital, The Netherlands.Gerbrich van den Bosch, MD, PhD, Erasmus MC – Sophia Children’s Hospital, The Netherlands.Sinno Simons, MD, PhD, Erasmus MC – Sophia Children’s Hospital, The Netherlands.Procedural sedation and analgesia in neonates poster.pdf-
-
- 1 reply
Featured by Stefan Johansson -
-
Call for Papers: Optimizing Enteral Nutrition in the NICU (Frontiers in Pediatrics)
Call for Papers: Optimizing Enteral Nutrition in the NICU (Frontiers in Pediatrics)
Dear Colleagues, As co-editor I'm pleased to invite you to contribute to our Research Topic in Frontiers in Pediatrics: "Optimizing enteral nutrition in the NICU: early feeding strategies, fortification approaches, and long-term growth outcomes in preterm and high-risk infants."We welcome Original Research, Reviews, Clinical Trials, Perspectives, and Case Reports that advance understanding of early nutrition’s impact on survival, growth, and neurodevelopment in preterm infants worldwide. The collection is peer-reviewed, and if we reach 10 published articles, a free Open Access eBook will be compiled.Key date: Manuscript deadline: 12 Feb 2027.Fees: Open Access publication fees apply. Institutional agreements, national consortia, and fee support options may be available. Eligibility and availability of financial support may vary. Fees are due only after acceptance.For the full scope and to submit, please visit: https://www.frontiersin.org/research-topics/84340/optimizing-enteral-nutrition-in-the-nicu-early-feeding-strategies-fortification-approaches-and-long-term-growth-outcomes-in-preterm-and-high-risk-infantsCarlos A. Delgado, MD, PhD. Pediatrician Neonatologist.Professor of Pediatrics. Universidad Nacional Mayor de San Marcos. Lima, PeruCo-Editor, Research Topic "Optimizing Enteral Nutrition in the NICU"-
-
- 0 replies
Featured by 99nicu.org -
-
Newborn Sepsis Society: Invitation for the Launch Event during CEPAS
Newborn Sepsis Society: Invitation for the Launch Event during CEPAS
Sepsis doesn't wait for a convenient hour, so neither will we. This Friday, 30 October, 08:00–09:00, the Newborn Sepsis Society launches in Europe at CEPAS 2026 in Lyon. Yes, it's early. We promise it's worth the alarm.📍 Room: St Clair 2New society, same goal: fewer newborns harmed by sepsis, and more of us working on it together. What to expect:🔹 Why a new society? Eleanor Molloy, Johan Gyllensvärd and Joanna Seliga-Siwecka (short answer: because babies deserve better, long answer: come and see)🔹 The problem: where are we in 2026? Joseph Ting🔹 The future: diagnostics and therapies. Eric Giannoni (evidence included, crystal ball optional)🔹 Open discussion: where do we go from here? You, with the microphoneFamilies have a seat at our table from day one, not as an afterthought. Mandy Daly will open the session with a message from our parent and public involvement committee.Already more than 100 members, and we've saved you a chair.💻 Can't make it to Lyon? Join us at newbornsepsissociety.orgSee you at 8:00 sharp (coffee optional, curiosity required).-
-
- 0 replies
Featured by piatkat -
Hot Forum Topics
-
The Codeine and Breastfeeding Controversy (2006-2026): How a Flawed Case Report Reshaped Neonatal Guidelines - and Why The Lancet Retracted It 20 Years Later
Dotan S ·Executive Summary and Clinical Context For nearly two decades, neonatal and obstetric clinical guidance regarding maternal analgesia was defined by an absolute prohibition: codeine is contraindicated during breastfeeding. Driven by warnings from the US Food and Drug Administration (FDA), European Medicines Agency (EMA), and health agencies worldwide, this dogma originated from a single 2006 case report in The Lancet describing the death of a 13-day-old infant from morphine overdose to which he w -
WHO standards for donor human milk banking
The World Health Organization has issued a global Standards for donor human milk banking, developed to ensure the safety, quality and ethical management of donor human milk. It is a thorough document, developed through systematic reviews, consideration of ethical issues and expert consensus. With the aim of providing harmonized, evidence-based guidance for policymakers, health systems and milk bank operators. Click here for more info on the WHO web site and click here or on the image below to do -
Ventilator graphics in BPD
How much do you deduce from ventilator graphics in an awake, sedated but active patient with severe BPD ? any thoughts on these images? are you worried about beaking of the PV loop, positive end expiratory flow suggestive of incomplete exhalation/emptying, notched expiratory limb of flow volume loop suggestive of obstruction to exhalation? M shape of the pressure scalar ? for the second image, beaking concern for the PV loop? -
USE OF ERYTHROPOIETIN (EPO) IN THE NEONATAL INTENSIVE CARE UNIT
We are three medical students from the University of Oviedo, Spain. We are collecting data on the different protocols for the use of EPO in neonatal units in european hospitals. If you could spend a few minutes completing this brief questionnaire about your experience in this field, it would help our research enormously. Thank you very much for your collaboration! https://urldefense.com/v3/__https://forms.cloud.microsoft/e/su0sDwb2qG__;!!D9dNQwwGXtA!X9cCjINSc1TgfJ0j_wuUOFALqWwZvcC-Rc7veFKMZAYVP -
Nephrogenic Diabetes Insipidus in neonate
Dear sir A 20-day-old term infant presents with lethargy and polyuria. Family history is significant for congenital Nephrogenic Diabetes Insipidus (NDI) in an older sister. Initial laboratory evaluation reveals a serum sodium level of 156 mEq/L. What is the optimal initial management strategy for this neonate, including the target rate of serum sodium correction and appropriate pharmacological intervention? -
International Survey on Discharge Practices for Preterm Infants (5 minutes)
Dear Colleagues, I hope this message finds you well. We are conducting an international survey on discharge practices for preterm infants. The goal is to understand current clinical practice across countries and to identify priorities for future research in this area. The questionnaire takes about 5 minutes to complete, and all responses will be anonymized. The study has been approved by the Institutional Review Board (IRB) of the Department of Health (DOH), Abu Dhabi. Survey link: International
Community News
-
20 years of 99nicu – and cake! 🎂
- 1 Comment
- 132 Views
-
CEPAS neonatology highlights
- 0 Comments
- 194 Views
-
Treasure hunt, networking pressure and a search for connection: come find us at CEPAS 2026
-
Newborn Sepsis Society: Invitation for the Launch Event during CEPAS
- 0 Comments
- 309 Views
Latest Blog Entries
-
Twenty Years of Unnecessary Pain
- 1 Comment
- 15 Views
-
#mypapers - It matters where extremely preterm infants are born (#2)
-
Gandhi & neonatal nutrition
- 1 Comment
- 490 Views
-
Because she was never meant to be alone
- 0 Comments
- 148 Views
NeoIPC Discussions
CollabLoading…
Professional Development
-
Evidence to Practice: Innovative Approaches to Surfactant Administration (VON Grand Round)
-
Healthy scepticism: how to read medical research critically
-
CEPAS is on
-
EBNEO Commentary: Clinician Opinion Disclosure and Parental Decision-Making in the Neonatal Intensive Care Unit
-
EBNEO Commentary: Duration of Antibiotic Therapy for Gram-Negative Bloodstream Infections in the Neonatal Intensive Care Unit
Latest Research From Neonatal Journals
- Cumulative perinatal risk and Sensory Over-Responsivity (SOR) at age eight. An epidemiological birth cohort study
- Emerging Insights into the Dysregulated Monocyte-Macrophage Axis in Necrotizing Enterocolitis
- Bolus Volume and Mortality in Extremely Low Gestational Age Infants with Shock
- Moving in the right direction? A survey of clinicians' opinions on wearable fetal movement monitoring devices
- Metabolic Profiles and insulin therapy requirements among pregnant women with Gestational Diabetes mellitus and Type 2 Diabetes across self-identified Race/ethnic groups in Brooklyn NY, USA
Latest in Links Directory
-
NeoBP (blood pressure charts)
- 0 Comments
- 3 Total Hits
-
Neonatal resuscitation simulator
- 0 Comments
- 16 Total Hits
-
Any guidance documents, recommendations, training courses and other resources on neonatal IPC to share?
- 0 Comments
- 0 Reviews
- 1 Total Hits
-
NICU Journeys: parents' stories, involvement in care and awareness of antimicrobial resistance
-
Video: The benefits of kangaroo care for premature babies and their families
-
NeoIPC Surveillance: How to and resources
- 0 Comments
- 0 Reviews
- 1 Total Hits
-
Video: The benefits of kangaroo care for premature babies and their families
- 0 Comments
- 0 Reviews
- 1 Total Hits
-
Neonatal TNE reporting tool
- 6 Comments
- 108 Total Hits
-
NeoIPC.org
- 0 Comments
- 0 Reviews
- 2 Total Hits
-
Preemie voices 2024
- 0 Comments
- 2 Total Hits
-
Preemie Voices 2014
- 0 Comments
-
Neonatology Now - the ESN Podcast
- 0 Comments
- 0 Reviews
- 9 Total Hits
Upcoming Events
-
1st NeoMeMo – Neonatology Conference: Mediterranean and More
1st NeoMeMo – Neonatology Conference: Mediterranean and More
1st NeoMeMo – Neonatology Conference: Mediterranean and More
28–29 November 2026 | Thessaloniki, Greece
The Hellenic Neonatal Society is pleased to invite you to the 1st Neonatology Conference: Mediterranean and More (1st NeoMeMo), taking place on 28–29 November 2026 in Thessaloniki, Greece.
The meeting will bring together neonatologists, pediatricians, nurses, researchers, and other healthcare professionals involved in newborn care from the Mediterranean region and beyond.
The scientific programme will focus on current and emerging topics in neonatal medicine, with lectures, clinical discussions, and opportunities for scientific exchange and networking.
The conference is organized by the Hellenic Neonatal Society and is held under the auspices of the Union of European Neonatal and Perinatal Societies (UENPS).
Venue: Thessaloniki, Greece
Dates: 28–29 November 2026
Registration and further information:
https://mk-premium.com/event/first-neonatology-conference-mediterranean-more/
28 November 2026 06:30 AM Until 29 November 2026 02:30 PM- 0 comments
-
Perinatal Care of the Preterm Baby Epidemiology and Ethics
Perinatal Care of the Preterm Baby Epidemiology and Ethics
Perinatal Care of the Preterm Baby-Epidemiology and Ethics
This is an online module being organised by the MPROvE Academy starting from the 12th of February till the end of April 2021. The content covered includes limits of viability, prenatal counselling, communication, prognostication, decision making, and a lot more as outlined below. The course has been broken up into content that can be imbibed weekly with a webinar covering that topic. The course has online content, and videos for review by the participants. Participants can access this from anywhere in the world. For more details a video of the course is attached.
For registration please contact Dr Alok Sharma Consultant Neonatologist on draloksharma74@gmail.com
25 December 2026 12:00 PM- 0 comments
-
"2027 Neonatal Ultrasound Course. Why,how and when an ultrasound image ?"
"2027 Neonatal Ultrasound Course. Why,how and when an ultrasound image ?"
It's the eighteenth edition of the International Course "2027 Neonatal Ultrasound Course. Why,how and when an ultrasound image ?".It's a Course open to neonatologists,paediatricians,paediatric radiologists,who like to learn Neonatal Ultrasonography. It's a webinar Course.The main topics: US Physics,Knobology in US,Quality Safety and Assurance in US,Neonatal brain US, Neonatal Chest,Lung and Spine US,Abdomen US(intestinal tract,liver,spleen,pancreas),Urogenital US,Small Parts US.Every lesson will have special tests for the participants.The recording of the lessons permit to watch them for two months.The lecturers are expert paediatric radiologists and excellent teachers.The Course's language is English.
2027 PROGRAMME NEONATAL US COURSE.pdf
15 March 2027 Until 18 March 2027- 0 comments
-
Update on Neurodevelopmental Care in NICU
Update on Neurodevelopmental Care in NICU
Update on
Neurodevelopmental Care in NICU
This workshop will concentrate on evidence-based therapeutic intervention programmes in the NICU and provide participants with tools, methods, and improved critical problem-solving abilities. An emphasis will be placed on the NICU environment, sensory experience, and feeding routines that best promote developmental care and offer neuroprotection. There will be group activities with practical takeaways for your own NICU.
1. Discuss key concepts of neuroprotection and stress in the NICU and how the neonatal therapist plays a role.
2. Prepare therapeutic interventions and strategies for the environment, positioning, feeding, sleep, and family support.
3. Develop developmental care for your practice with the very low birth weight infant, the late preterm, and infants with HIE.
4. Demonstrate at least 25 strategies learned to create change in the NICU regarding neurodevelopmental care.
FOR REGISTRATION
18 March 2027 03:30 AM Until 21 March 2027 11:30 AM- 1 comment
Who's Online (See full list)
Member Statistics
- 7,074 Total Members
- 2,455 Most Online
-
GhaFak Newest Member ·